Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · Real-Time Price · USD

13.31

+0.39 (3.02%)

At close: Jul 28, 2026, 4:00 PM EDT

13.05

-0.26 (-1.95%)

After-hours: Jul 28, 2026, 7:34 PM EDT

Corvus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	40.1	4.58	8.74	12.62	13.16	63.46
Short-Term Investments	196.61	52.17	43.22	14.53	29.14	5.99
Cash & Short-Term Investments	236.71	56.75	51.96	27.15	42.3	69.45
Cash Growth	435.41%	9.21%	91.40%	-35.82%	-39.09%	56.92%
Accounts Receivable	0.04	0.04	0.08	0.03	0.59	0.51
Other Current Assets	3.19	1.43	2.37	0.78	0.77	1.35
Total Current Assets	239.95	58.21	54.41	27.96	43.66	71.31
Net Property, Plant & Equipment	1.03	1.06	1.33	1.39	2.57	3.64
Long-Term Investments	10.5	10.99	12.54	16.12	21.88	34.27
Other Long-Term Assets	1.72	0.86	0.63	0.09	0.13	0.24
Total Assets	253.2	71.12	68.91	45.55	68.24	109.46

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	4.7	2.49	2.58	1.53	1.98	1.57
Accrued Expenses	6.99	6.49	3.73	3.97	7.55	7.08
Current Portion of Leases	0.43	0.4	0.19	1.37	1.23	1.05
Other Current Liabilities	-	-	28.91	-	-	-
Total Current Liabilities	12.11	9.38	35.4	6.87	10.75	9.69
Long-Term Leases	0.41	0.53	0.94	-	1.37	2.6
Total Long-Term Liabilities	0.41	0.53	0.94	-	1.37	2.6
Total Liabilities	12.52	9.91	36.34	6.87	12.13	12.29

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	667.78	474.39	430.86	374.36	364.36	361.67
Accumulated Other Comprehensive Income	-1.13	-0.9	-1.29	-0.97	-0.56	1.87
Retained Earnings	-425.99	-412.29	-397.01	-334.72	-307.69	-266.38
Shareholders' Equity	240.68	61.21	32.57	38.68	56.12	97.16
Total Liabilities & Equity	253.2	71.12	68.91	45.55	68.24	109.46

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	0.83	0.94	1.12	1.37	2.6	3.65
Net Cash (Debt)	235.88	55.81	50.84	25.78	39.7	65.8
Net Cash Growth	447.81%	9.78%	97.25%	-35.08%	-39.67%	56.87%
Net Cash Per Share	2.83	0.70	0.83	0.54	0.85	1.57
Book Value	240.68	61.21	32.57	38.68	56.12	97.16
Book Value Per Share	2.89	0.77	0.53	0.81	1.21	2.32
Tangible Book Value	240.68	61.21	32.57	38.68	56.12	97.16
Tangible Book Value Per Share	2.89	0.77	0.53	0.81	1.21	2.32

SEC Filings: 10-K · 10-Q